European High Growth Opportunities Securitization Fund gives notice of exercise of warrants

European High Growth Opportunities Securitization Fund has by notice to the board of directors of Cereno Scientific AB (publ) (“Cereno”) called upon its right to exercise warrants previously issued in accordance with the financing solution announced by Cereno through a press release on 19 March 2018.

Cereno has received notification from European High Growth Opportunities Securitization Fund regarding exercise of 1,105,262 warrants, which using the exercise ratio given by the agreement have right to 1,440,156 class B shares in Cereno. The subscription price per share is SEK 1.46. Upon registration at the Swedish Companies Registration Office, Cereno’s total share capital will amount to SEK 10,670,193.8 divided into 106,701,938 shares of which 722,248 shares of series A and 105,979,690 shares of series B.

For further information, please contact:

Daniel Brodén, CFO
Phone: +46 768 66 77 87
Email: info@cerenoscientific.com
http://www.cerenoscientific.com/

This information is information that Cereno Scientific AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 11:45 CET on December 7, 2021.

About Cereno Scientific AB
Cereno Scientific is a clinical stage biotech company within cardiovascular diseases. The lead drug candidate, CS1, is a Phase II candidate in development for the treatment of the rare disease pulmonary arterial hypertension (PAH) and thrombotic indications. CS1 is an HDAC (Histone DeACetylase) inhibitor that acts as an epigenetic modulator with anti-thrombotic, anti-inflammatory, anti-fibrotic and pressure-relieving properties, all relevant for PAH. In addition, Cereno has two promising preclinical development programs named CS014 and CS585 targeted at treating cardiovascular diseases. The company is headquartered in AstraZeneca’s BioVenture Hub, Sweden, and has a US subsidiary Cereno Scientific Inc. based in Kendall Square in Boston, Massachusetts, US. Cereno is listed on the Swedish Spotlight Stock Market (CRNO B). More information on www.cerenoscientific.com.